AbbVie Q2 FY25: where the revenue came from and where it went
The whole income statement of AbbVie for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Aug 4, 2025
Revenue$15.4B
+7% year over year
Gross profit$11.1B
72% margin
Operating profit$4.9B
32% margin
Net profit$0.9B
6% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 15.4 | 100% | +7% |
| Skyrizi | 4.4 | 29% | |
| Neuroscience | 2.7 | 17% | |
| Rinvoq | 2.0 | 13% | |
| Oncology | 1.7 | 11% | |
| Other revenue | 1.3 | 9% | |
| Aesthetics | 1.3 | 8% | |
| Humira | 1.2 | 8% | |
| Other key products | 0.8 | 5% | |
| Cost of revenue | −4.3 | 28% | |
| Gross profit | 11.1 | 72% margin | +1pp |
| SG&A | −3.3 | 21% | −2pp |
| Other | −2.9 | 19% | +0pp |
| Operating profit | 4.9 | 32% margin | +4pp |
| Interest & other costs | −3.3 | ||
| Tax | −0.6 | ||
| Net profit | 0.9 | 6% margin | −3pp |
181 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest